Status:
UNKNOWN
The Angiotensin Converting Enzyme (ACE) Inhibitor SwitchBack Study
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborating Sponsors:
Servier
Conditions:
Heart Failure
Eligibility:
All Genders
Brief Summary
ACE inhibitors have been studied extensively in the treatment of heart failure and have been shown to be beneficial in all its stages. Studies with the use of angiotensin receptor blockers (ARBs) in c...
Eligibility Criteria
Inclusion
- heart failure patients who have indications for ACEi but are currently on ARBs with no absolute contraindications to ACEi
- patients with an ejection fraction of \< or = 35% verified in the last 12 months by echo, angio, or nuc med who are NYHA class I to IV and followed in a heart failure clinic for three months
- on beta-blockers, unless contra-indicated
- stable on current meds for 3 months (except dose of diuretics)
- able to give informed consent
Exclusion
- documented angioedema/anaphylaxis with prior ACEi use
- documented worsening renal failure, hyperkalemia, cough and gastrointestinal symptoms that are definitely believed to be due to ACEi
- potassium \>5.0 mmol/L
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2012
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01162980
Start Date
July 1 2010
End Date
July 1 2012
Last Update
July 15 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Victoria Hospital
Montreal, Quebec, Canada, H3A 1A1